Valbiotis Stock

Valbiotis Equity

The The Equity of Valbiotis (ALVAL.PA) as of Aug 13, 2026 is 10.37 M EUR. In the previous year, The Equity was 19.60 M EUR — a change of -47.10% (lower).

Equity

10.37 MEUR

YoY

-47.10%

Last updated:

In 2026, Valbiotis's equity was 10.37 M EUR, a -47.10% increase from the 19.60 M EUR equity in the previous year.

Access this data via the Eulerpool API

Valbiotis Stock analysis

What does Valbiotis do? Valbiotis SA is a French company specializing in the research and development of new and innovative treatment options based on plant-derived ingredients. The company was founded in 2014 by Sebastien Peltier, an experienced employee in the pharmaceutical industry, who wanted to search for new and effective therapeutic possibilities. Valbiotis' business model is based on identifying and utilizing new plant-derived ingredients to develop therapies that cater to market needs. The company works closely with various partners, universities, and research organizations to ensure that their products are based on the latest scientific findings. One of Valbiotis' main areas of focus is the development of products to support metabolism and metabolic health. They utilize solutions based on a plant-derived ingredient called TOTUM-63, which aims to treat and prevent risk factors such as obesity, insulin resistance, and metabolic diseases like Type 2 diabetes. Valbiotis has also established a comprehensive research department to explore further applications for their plant-derived ingredients, including cardiovascular diseases and neurodegenerative diseases like Alzheimer's. One of Valbiotis' most well-known products is TOTUM-63, a plant-derived ingredient that has positive effects on metabolism. TOTUM-63 consists of four different plant-derived ingredients and is intended to restore balance to metabolism and support the body in combating risk factors such as obesity and Type 2 diabetes. The company is currently seeking further promising applications for TOTUM-63. Valbiotis has also formed partnerships with major pharmaceutical companies such as Nestlé Health Science and Nestlé Research to fund their research and optimize the use of their plant-derived ingredients. Additionally, Valbiotis collaborates with various universities and research institutions to incorporate the latest scientific findings into their products. Overall, Valbiotis is one of the most promising companies in the pharmaceutical industry focused on plant-derived ingredients. The company has developed a wide range of products and applications and works closely with various partners to develop innovative therapy options based on plant-derived ingredients. Valbiotis is well-positioned to achieve further growth in the future and treat and prevent diseases in a new way. Valbiotis is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Valbiotis's Equity

Valbiotis's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Valbiotis's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Valbiotis's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Valbiotis's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Valbiotis’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Valbiotis stock

The Equity of Valbiotis is 10.37 M EUR in 2026.

The Equity of Valbiotis changed from 19.60 M EUR to 10.37 M EUR, representing a -47.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Valbiotis since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Valbiotis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Valbiotis

All Key Metrics — Valbiotis